Early Steroid Withdrawal after Liver Transplantation: The Canadian Tacrolimus versus Microemulsion Cyclosporin A Trial: 1-year Follow-up
Dr. Vivian McAlister is currently a faculty member at The University of Western Ontario.
Corticosteroid therapy contributes significant toxicity to liver transplantation. The safety and efficacy of early steroid withdrawal were determined in patients treated with either tacrolimus or microemulsion cyclosporin A (micro-CsA). The primary outcome was the proportion of patients who were steroid-free 1 year posttransplantation. From the seven Canadian adult liver transplant centers, 143 patients were randomly allocated oral treatment with either tacrolimus (n = 71) or micro-CsA (n = 72), together with corticosteroids and azathioprine. Eligibility criteria for steroid withdrawal included freedom from acute rejection for a minimum of 3 months, and prednisone
Paul Greig, Leslie Lilly, Charles Scudamore, Siegfried Erb, Eric Yoshida, Norman Kneteman, Vince Bain, Cameron Ghent, Paul Marotta, David Grant, William Wall, Jean Tchervenkov, Jeffrey Barkun, Andre Roy, Denis Marleau, Vivian McAlister, and Kevork Peltekian. "Early Steroid Withdrawal after Liver Transplantation: The Canadian Tacrolimus versus Microemulsion Cyclosporin A Trial: 1-year Follow-up" Liver Transplantation 9.6 (2003): 587-595.
Available at: http://works.bepress.com/vivianmcalister/79